title: Drug interaction between sunitinib and cimetidine and contribution of the efflux transporter ATP-binding cassette C2 to biliary excretion of sunitinib in rats.
abstract: The present study investigated the effect of the H2 antagonist cimetidine on the pharmacokinetics of a multi-targeted receptor tyrosine kinase (RTK) inhibitor, sunitinib, in Sprague-Dawley (SD) rats and Eisai hyperbilirubinemic mutant rats (EHBR) lacking the efflux transporter, ATP-binding cassette C2 protein (ABCC2). Rats received an intraperitoneal injection of cimetidine (10 mg/kg) once a day for three days. On day 4, sunitinib (3 mg/kg) was administered intravenously 30 min after the final injection of cimetidine or saline to SD rats. Disappearance of sunitinib from plasma was significantly delayed by cimetidine. The pharmacokinetic parameter of sunitinib, systemic clearance (CLSYS), was significantly reduced and the half-life was significantly prolonged, with no change in the volume of distribution at steady-state (VSS). When the effect of cimetidine on the biliary excretion of sunitinib at steady-state condition was investigated in SD rats, cimetidine had no effect on some transporter-mediated biliary excretion of sunitinib. Furthermore, the contribution of ABCC2 to the biliary excretion of sunitinib was also examined in SD rats and EHBR. The biliary clearance of sunitinib was significantly lower in EHBR, but the biliary excretion rate of EHBR was not different from that of SD rats, and the contribution of biliary excretion to systemic elimination was small, suggesting that sunitinib is mainly eliminated by cytochrome P450 3A4 (CYP3A4)-mediated metabolism and is not excreted into the bile via ABCC2. These findings indicate that co-administration of cimetidine alters the pharmacokinetics of sunitinib probably due to inhibition of CYP3A4, suggesting the possibility that cimetidine should be used carefully for patients with cancer being treated with sunitinib therapy.
authors.affiliation: Department of Hospital Pharmacy and Pharmacokinetics, Aichi Medical University School of Medicine, Karimata, Yazako, Nagakute, Aichi 480-1195, Japan.
authors.forename: Maki
authors.initials: M
authors.lastname: Arakawa-Todo
authors.forename: Jun
authors.initials: J
authors.lastname: Ueyama
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Nomura
authors.forename: Fumie
authors.initials: F
authors.lastname: Abe
authors.forename: Ikuto
authors.initials: I
authors.lastname: Tsukiyama
authors.forename: Katsuhiko
authors.initials: K
authors.lastname: Matsuura
authors.forename: Takaaki
authors.initials: T
authors.lastname: Hasegawa
mesh_terms: D018528:ATP-Binding Cassette Transporters / Q000378:metabolism*; D000818:Animals; D001646:Bile / Q000378:metabolism*; D002927:Cimetidine / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D004347:Drug Interactions; D006932:Hyperbilirubinemia / Q000097:blood / Q000188:drug therapy; D007211:Indoles / Q000008:administration & dosage / Q000097:blood / Q000737:chemistry / Q000493:pharmacokinetics*; D007275:Injections, Intravenous; D008297:Male; D013058:Mass Spectrometry; D011758:Pyrroles / Q000008:administration & dosage / Q000097:blood / Q000737:chemistry / Q000493:pharmacokinetics*; D051381:Rats; D011922:Rats, Mutant Strains; D017207:Rats, Sprague-Dawley; D000077210:Sunitinib
chemical_list: D018528:ATP-Binding Cassette Transporters; C423013:Abcc2 protein, rat; D007211:Indoles; D011758:Pyrroles; D002927:Cimetidine; D000077210:Sunitinib
keywords: (Abcc2); Biliary excretion; cimetidine; drug interaction; multidrug resistance-associated protein-2 (Mrp2); pharmacokinetics; sunitinib